SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Calmare Therapeutics Inc. (CTTC)

CTTC RSS Feed
Add CTTC Price Alert      Hide Sticky   Hide Intro
Moderator: conix, mog1962
Search This Board: 
Last Post: 9/18/2017 9:53:23 PM - Followers: 37 - Board type: Free - Posts Today: 0

 

                                                                      

Calmare Therapuetics Incorporated.,  (OTCQX: CTTC)


MAYO CLINIC News on Calmare (November, 2014) 
http://www.reuters.com/video/2014/09/30/scrambling-away-pain-for-cancer-patients?videoId=346379225&videoChannel=6  
 

   
 
  



 ________________________________________________________________________________________________________________________________

 

Only machine of its kind in SC appears to get results for patients in pain

Helen Adams | adamshel@musc.edu | May 18, 2017

 

Retired teacher Douglas Foxworth was suffering from pain so severe that it felt like his feet were on fire. The cause was unknown — it’s called idiopathic peripheral neuropathy. When the Sumter man heard about a new pain treatment at MUSC Health called scrambler therapy, he jumped at the chance to try it.

“That morning when I went in, I was practically in tears. When they asked how my pain was, I said a nine, pushing a ‘ten’ out of ten,” Foxworth said.

He became one of the first patients in South Carolina to try scrambler therapy. The scrambler device, by Calmare, has been cleared by the Food and Drug Administration. Nurse Julie Watson described how it works. “The scrambler therapy device uses transcutaneous electrical stimulation to replace maladaptive pain information with ‘non-painful’ or ‘normal’ messages. It does this by traveling along the same pathways to the brain.” 

In other words, as its name suggests, scrambler uses electrical stimulation on the skin to scramble what nerves are trying to tell the brain. Each treatment lasts between a half-hour and 45 minutes. Foxworth had 12 sessions over a 2 1/2-week period. “The first day when they put those electrodes on, about 10 or 15 minutes after, the pain level went down,” he said. “It didn’t last, but the pain level went down to where it was tolerable.”

By the end of the 12th session, the difference was dramatic. “I still have some pain, but I’m no longer on pain medication. The pain is very mild,” Foxworth said. “I consider that this was effective to eliminate probably 90 percent of my pain.”

Palliative care specialist Pat Coyne, who introduced scrambler therapy at MUSC Health, said about 80 percent of the patients who try it feel a substantial difference. He first heard about scrambler therapy while he was working at Virginia Commonwealth University. “We did three research studies,” he said. “We went into the research trying to prove it didn’t work, and everyone kept saying they felt better.”

The skepticism Coyne initially felt resonates with MUSC Health palliative care doctor John Gibson. “Our team has been very happy with the results we have seen,” Gibson said. “I think the biggest point of skepticism for everyone who sees scrambler is that no one really understands how it works. There are theories that make sense, but no one has proven how it works.”

Scrambler therapy was invented by an Italian professor, Coyne said. It has been around for almost two decades, but wasn’t introduced in the U.S. until around 2010. The device requires careful monitoring. “With the electrodes, it senses the nerve firing. The electricity comes in wave forms and pulses. You adjust those based on when the patient tells you the pain is going away,” Coyne said. 

His research team wasn’t alone in finding scrambler therapy was effective. An article in the journal Supportive Care in Cancer said 19 out of 20 reports on scrambler therapy came up with positive results.

It’s a nuanced treatment, Coyne said. “A nurse is going to be sitting at the bedside and adjusting the dials. It will be different each time, and the leads will change because the pain typically gets smaller with each treatment. Really, what it’s trying to do is, when the nerves fire, it’s firing against them. So the pulsation never makes it to the brain and you don’t feel pain. And in doing so, we know it changes the way calcium is absorbed. Nerves that fire a lot actually are sometimes calcium deprived. You’re trying to reset the nerves to normal.”

Coyne said research shows patients who had scrambler therapy showed improvements in their natural pain-fighting reserves. “They get depleted when they’re fighting pain all the time. We found their endorphins changed.”

During a training period at MUSC Health, patients could volunteer to try scrambler therapy. It’s now in use in MUSC Hollings Cancer Center, covered by Medicare, Medicaid, and some insurance providers. “Starting off, we’re going to focus on the cancer population, but it’s going to be open to anyone who has this nerve pain,” Coyne said.

Watson, who has treated patients with the scrambler, said cancer treatments can cause neuropathic pain and sensation problems. “They may be able to stay on their treatments longer or at doses they may not have been able to previously tolerate. This treatment can be life-changing for some by enhancing quality of life and allowing them to do activities they may not have previously been able to do,” Watson said. 

“We treated a patient with chemo-induced neuropathy, and he wanted to work out and jump rope as he once did. Before he completed his treatments, his numbness had improved so much in his feet that he began jumping rope, which he had not been able to do for several years. Having a non-invasive, non-pharmacological alternative such as scrambler therapy that has shown proven benefit for neuropathic pain is a tremendous stride here at MUSC Health.”

Gibson, the palliative care physician, said it’s important to look for new ways of treating pain. “Unfortunately, and despite years of effort, the health system does not do a great job of treating pain, particularly neuropathic pain, which is really what scrambler is targeted toward,” he said.

“The mainstay of treatment currently is drugs, all of which come with a number of side effects. In many instances, these medicines do not adequately control the pain or cannot be tolerated by the patient. Among these medications are the opioids, which pose possible risks to the patient, and as everyone now has seen commonly on the news, opioids come with a heavy burden on our public health," Gibson said.

Neuropathic pain, particularly chemotherapy-induced neuropathy, is typically a chronic form of pain. "There is very little evidence that opioids are effective in chronic pain, and there are significant issues with tolerance to these medicines which often leads patients to higher and higher doses of the medicine, usually with more side effects," Gibson said. "Scrambler offers the potential to significantly reduce the patient’s pain with basically no side effects and no ongoing need to take pills. Without the pills, many of the societal burdens of pain medicines will be reduced as well.”

Coyne envisions having several scrambler devices at MUSC Health in the future. With scrambler therapy, he said, “The numbness goes away, which no one’s ever found a way to fix. Some meds take away the pain, but the numbness stays.”

To be treated with scrambler therapy at MUSC Health, patients must have a referral from a doctor. Watson said common conditions treated include chemo-induced neuropathy, diabetic neuropathy, phantom limb pain, failed back syndrome, trigeminal neuralgia, postherpetic neuralgia and chronic regional pain syndrome.

Before scrambler therapy, Foxworth, the teacher from Sumter, was taking the pain reliever gabapentin. He’s not anymore, but knows his pain may flare up again. “More than likely it will reoccur. When that happens, I’ll go back for what they call a booster treatment. I’m very pleased with what scrambler therapy has done for me."

http://academicdepartments.musc.edu/newscenter/2017/scrambler/index.html]b\[

-----------------------------------------------------------------------------------------
 

Berkeley, California Neurology Practice Adds Calmare(R) Pain Management Therapy

Dr. Selena Ellis to Treat Chronic Neuropathic Pain with Non-Invasive and Non-Addictive Technology

BERKELEY, CA - (NewMediaWire) - June 13, 2017 - Dr. Selena Ellis (www.selenaellismd.com) is proud to announce her medical practice will be the first neurology practice in the western United States to offer Calmare® therapy, an effective non-opioid treatment for neuropathic pain. Dr. Ellis's medical practice treats chronic pain in patients suffering from trigeminal neuralgia, peripheral neuropathy, complex regional pain syndrome (CRPS), headaches and migraines. After an in-depth evaluation process which included the successful treatment of her patients with chronic neuropathic pain, Dr. Ellis has recently added this very promising therapy, also known as "Scrambler Therapy".https://www.foundationforpn.org/2016/12/09/scrambler-therapy-for-treating-neuropathic-pain/)

Calmare® is a FDA-cleared device that provides a non-invasive therapy for the treatment of chronic neuropathic pain. Calmare® therapy has also been successful in achieving chronic pain relief for patients suffering from failed surgical back syndrome and multiple neuropathies including chemotherapy-induced peripheral neuropathy (CIPN). http://www.reuters.com/video/2014/09/30/scrambling-away-pain-for-cancer-patients?videoId=346379225&videoChannel=6.

Significantly, there have been no reports of adverse side effects associated with this therapeutic modality.

The Calmare® technology employs electrostimulation with a low electrical current directed at the central nervous system and delivered through applied electrodes on the patient's skin surrounding the pain area. Sixteen electrical impulse algorithms are programmed to specifically target the body's sensory fiber pathway (which transmits slower and chronic pain signals). These electrical signals help "re-program" the brain's receipt of the pain signal. In many patients, these signals provide longer-lasting pain relief than those that "blocking" the pain signal, such as with transcutaneous electrical nerve stimulation (TENS).

Treatment

Physicians using Calmare therapy have reported that patients who experience a reduction in pain after their first 45-minute treatment have a high probability of experiencing a significant reduction in chronic pain after completing a ten-treatment regimen. Patients should be weaned off certain medications before starting the therapy to achieve the best result.

Dr. Ellis says, "My practice focuses on providing chronic pain relief to my patients using the most safe, effective and non-addictive therapies available. As a neurologist, I am open to new modalities after conducting a complete evaluation of the patient. After I saw the positive results in some of my patients after using Calmare, I knew I wanted to be the first neurologist to offer the technology in the western US."

About Selena Ellis, MD (www.selenaellismd.com)

Dr. Ellis attended medical school at the University of Washington in Seattle and completed her neurology residency at the UCLA School of Medicine in 2002. She obtained subspecialty training in electrodiagnosis of neuromuscular disease as Chief Resident and Fellow at the Wadsworth VA/UCLA Department of Neurology.

Dr. Ellis is board-certified in general neurology and electrodiagnostic medicine by the American Board of Psychiatry and Neurology (ABPN) and the American Board of Electrodiagnostic Medicine (AANEM). She was the president and longtime board member of the San Francisco Neurological Society http://www.sfneurological.org/board.html. Dr. Ellis had the first medical practice in Northern California with an AANEM-certified electromyogram (EMG) lab, in addition to being the first neurologist in the western US to offer Calmare therapy.

Dr. Ellis treats common neurological disorders such as headache, peripheral neuropathy, trigeminal neuralgia, occipital neuralgia, complex regional pain syndrome, back pain, and sciatica. Other common symptoms treated at her practice include pain syndromes of many types, difficulty with gait or balance, and sensory changes to the arms or legs. Dr. Ellis also has subspecialty training in evaluation and management of problems affecting the peripheral nervous system, including systemic neuropathies, mononeuropathy and radiculopathy.

About Calmare/Scrambler Therapy

Distributed by Competitive Technologies, Inc., the Calmare® (also known as Scrambler therapy) is a U.S. FDA 510(k)-cleared and European CE mark-certified pain therapy medical device for the non-invasive and non-narcotic treatment of chronic neuropathic and oncologic pain. Using a biophysical rather than a biochemical approach, Calmare employs a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin surrounding the area in pain. The device creates and relays a non-pain signal which becomes the dominant signal received by the brain and overrides the pain signal to provide relief for the patient. The Calmare device has been used to successfully treat over 10,000 chronic pain patients worldwide. 

Contact:

Cynthia Laird at 510-644-2282 for Dr. Selena Ellis or
officemanager@selenaellismd.com

http://www.newmediawire.com/news/berkeley-california-neurology-practice-adds-calmare-r-pain-management-therapy-4818055


--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
CTTC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTTC News: Current Report Filing (8-k) 09/14/2017 02:26:24 PM
CTTC News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 08/16/2017 04:50:19 PM
CTTC News: Annual Report (10-k) 07/21/2017 05:00:30 PM
CTTC News: Statement of Beneficial Ownership (sc 13d) 06/30/2017 05:06:06 PM
CTTC News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 03/31/2017 04:42:45 PM
PostSubject
#14446   I am a SH of this dog poo Munchqin 09/18/17 09:53:23 PM
#14445   May not be able to find anyone who andy55q 09/18/17 04:27:22 PM
#14444   Do you know any current shareholders? If conix 09/18/17 09:33:08 AM
#14443   The New York times is starting to get it. powderbum 09/18/17 09:31:41 AM
#14442   I think shareholders should be demanding an annual meeting. powderbum 09/18/17 09:29:53 AM
#14441   Nobody wants financials filed on time and an powderbum 09/18/17 09:27:33 AM
#14440   Watch the language. Frustration is understandable, especially if conix 09/17/17 04:59:54 PM
#14439   So what? Munchqin 09/16/17 11:06:32 PM
#14438   A reason why this MF'ing company (run by Munchqin 09/16/17 11:02:51 PM
#14437   http://www.totalrehabclinics.com/calmare--pain-therapy One of the best Cal powderbum 09/16/17 01:10:29 PM
#14436   Another update on Lewis lawsuit against CTTC: nobodysbusiness 09/16/17 09:32:55 AM
#14435   Around, around they go --GEOMC lawsuit against CTTC update: nobodysbusiness 09/16/17 09:29:59 AM
#14434   I was not able to open the letter mog1962 09/15/17 01:04:50 PM
#14433   I wonder what it takes to audit the mog1962 09/15/17 11:29:12 AM
#14432   New accounting firm: nobodysbusiness 09/15/17 09:28:45 AM
#14431   Yet ANOTHER update of GEOMC versus CTTC: nobodysbusiness 09/15/17 07:25:30 AM
#14430   Something tomorrow in GEOMC lawsuit against CTTC: nobodysbusiness 09/14/17 09:29:40 PM
#14429   Lewis lawsuit against CTTC update: nobodysbusiness 09/14/17 09:27:40 PM
#14428   Another pain drug having serious problems powderbum 09/14/17 02:02:32 PM
#14427   Give me a break. What research doctor tells powderbum 09/14/17 02:01:59 PM
#14426   powderbum you are correct as to long lead time mog1962 09/14/17 11:37:58 AM
#14425   20 Vets commit suicide everyday related to pain powderbum 09/14/17 10:04:20 AM
#14424   Everything you said was a misrepresentation. Every researcher powderbum 09/14/17 10:03:04 AM
#14423   SORRY! BUT THE THESE TWO STUDIES with PUBLISHED Munchqin 09/13/17 10:12:41 PM
#14422   Let's start with FDA approval!!!!!!!!!!! andy55q 09/13/17 04:41:22 PM
#14421   There are two controlled studies that show Calmare powderbum 09/13/17 01:17:53 PM
#14420   powderbum I doubt that anyone on this message board mog1962 09/13/17 12:23:31 PM
#14419   Does anything having to with CTTC ever NOT nobodysbusiness 09/13/17 11:36:57 AM
#14418   70% of Americans don't want drugs to treat pain powderbum 09/13/17 09:48:34 AM
#14417   I thought from the original post that Bryan mog1962 09/12/17 02:34:05 PM
#14416   My Lord and My God, Please forgive me Munchqin 09/11/17 11:16:43 PM
#14415   Details of bryan Clark suit are at: nobodysbusiness 09/11/17 06:26:38 PM
#14414   http://civilinquiry.jud.ct.gov/PartySearch.aspx andy55q 09/11/17 03:03:27 PM
#14413   State of CT , Judicial web site andy55q 09/11/17 12:47:37 PM
#14412   Andy Which of the many cases is he part mog1962 09/11/17 10:40:38 AM
#14411   BRYAN CLARK andy55q 09/11/17 08:22:34 AM
#14410   Excessive Pain Medication Use Seen as Factor in conix 09/09/17 01:08:56 PM
#14409   GEOMC lawsuit update: nobodysbusiness 09/09/17 12:33:58 PM
#14408   Excessive Pain Medication Use Seen as Factor in conix 09/09/17 09:49:35 AM
#14407   Posting stories and fairy tales does nothing to Munchqin 09/08/17 09:38:10 PM
#14406   Your 3rd grade vocabulary is becoming predictable. Are powderbum 09/08/17 12:06:50 AM
#14405   Your 3rd grade vocabulary is becoming predictable. Are powderbum 09/08/17 12:06:47 AM
#14403   At least Nano was a LITTLE interesting! May nobodysbusiness 09/07/17 09:36:24 PM
#14402   Ok. We will see a PR tomorrow? andy55q 09/07/17 08:48:21 PM
#14401   Another great Australian Calmare story powderbum 09/07/17 08:32:34 PM
#14400   Fair point. This company has now PR or IR. powderbum 09/07/17 08:31:29 PM
#14399   10q out tomorrow andy55q 09/07/17 12:40:39 PM
#14398   At least John Nano communicated with the shareholders, mog1962 09/07/17 10:13:44 AM
#14397   "We are at the start of an exciting andy55q 09/06/17 06:51:15 PM
#14396   Just an idle thought..... mog1962 09/06/17 05:50:01 PM
PostSubject